Credits Earned (2024) Crédits obtenus

Redeem Prepaid Membership

Tools for Practice Outils pour la pratique


#1 CRP = CV?: Should We React to C-Reactive Protein?


CLINICAL QUESTION
QUESTION CLINIQUE
Is high-sensitivity C-reactive protein (hs-CRP) useful in guiding the management cardiovascular (CV) disease primary prevention?


BOTTOM LINE
RÉSULTAT FINAL
hs-CRP is not useful at identifying patients at risk of a CV event or those who may benefit from primary prevention interventions.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
JUPITER1 is used by some to justify hs-CRP testing to guide intervention for primary prevention of CV disease: 
  • Randomized controlled trial (RCT) (~90,000 screened17,802 includedwith LDL <3.4 mmol/L and hs-CRP ≥2 mg/L followed for median 1.9 years. 
    • CV events: Rosuvastatin 1.6% vs. placebo 2.8%, Number Needed to Treat (NNT)=82. 
    • All-cause mortality: Rosuvastatin 2.2% vs. placebo 2.8%, NNT=182. 
    • Several limitations:2 
      • Early study termination (which tends to exaggerate benefits3). 
      • Poor generalizability due to strict eligibility criteria. 
      • Sponsorship bias. 
      • Incomplete outcome reporting.
NRCT exists where patients are randomized to hs-CRP testing or no testing to guide therapy initiation     Context:  
  • Meta-analysis4 of 52 prospective studies (246,669 patients) found that adding hs-CRP to traditional CV risk factors (i.e. Framingham calculatordid not better identify those at risk of CV events. 
  • JUPITER added virtually nothing to statin management in primary prevention: 
    • Statins reduce CV events by relative ~25-30% across the population5 (regardless of hs-CRP6)and absolute benefit depends on patient’s individual CV risk.5 
    • Mean CRP in JUPITER would change risk obtained from Framingham calculator by only ~1-3%, which has little/no effect on treatment benefits and therefore should not influence decisions.7 
      • Example: Statin therapy reduces absolute risk by 4.5% (if baseline risk=18%) vs. 5.25% (if baseline risk=21%). 
  • hs-CRP varies widely from one measurement to the next,8,9 meaning single measurements are insufficient for decision-making. 
  • Reductions in hs-CRP are not consistently predictive of improved outcomes. 
    • Vitamin A, rosiglitazone and rofecoxib reduced hs-CRP, but worsen clinical outcomes.7 
  • Updated Canadian dyslipidemia guidelines no longer recommend routine use of hs-CRP to stratify patients, including those at “intermediate risk.10 
  Last Reviewed: July 13, 2016 by Ricky D Turgeon BSc(Pharm) ACPR PharmD 


Latest Tools for Practice
Derniers outils pour la pratique

#374 Vitamin D and Fracture Prevention: Not what it’s cracked up to be?

Does vitamin D prevent fragility fractures?
Read Lire 0.25 credits available Crédits disponibles

#373 Strategies for initiating insulin in type 2 diabetes

What is the optimal initial insulin for patients with type 2 diabetes?
Read Lire 0.25 credits available Crédits disponibles

#372 Mission Slimpossible Part 2: Oral GLP-1 agonists for weight loss

Are oral GLP-1 agonists effective for weight loss?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • G. Michael Allan MD CCFP

1. Ridker PM, Danielson E, Fonseca FA, et al. N Engl J Med. 2008; 359:2195-207.

2. de Lorgeril M, Salen P, Abramson J, et al. Arch Intern Med. 2010; 170:1032-6.

3. Bassler D, Briel M, Montori VM, et al. JAMA. 2010; 303:1180-7.

4. The Emerging Risk Factors Collaboration. N Engl J Med. 2012; 367:1310-20.

5. Cholesterol Treatment Trialists’ Collaborators. Lancet. 2012; 380:581-90.

6. Heart Protection Study Collaborative Group. Lancet. 2011; 377:469-76.

7. McCormack JP, Allan GM. PLoS Med. 2010; 7:e1000196.

8. Koenig W, Sund M, Frohlich M, et al. Am J Epidemiol. 2003; 158:357-64.

9. Bogaty P, Brophy JM, Boyer L, et al. Arch Intern Med. 2005; 165:221-6.

10. Anderson TJ, Gregoire J, Hegele RA, et al. Can J Cardiol. 2013; 29:151-67.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 13/07/2016

By: Ricky D. Turgeon, B. Sc. (Pharm), ACPR, Pharm. D.; G. Michael Allan, M.D., CCMF

Comments:

Evidence: No new evidence; Bottom line: No change.

Learning at a glance
Yearly credits
Acquired ()
Your content by topic
Cardiology Dermatology Emergency
My Bookmarks